News & Updates
Filter by Specialty:
Enfortumab vedotin-pembrolizumab beats chemo as 1L Tx for bladder cancer
In the phase III EV-302/KEYNOTE-A39 trial, the combination of enfortumab vedotin and pembrolizumab (EV+P) had a significant survival advantage over chemotherapy in the first-line treatment of patients with locally advanced metastatic urothelial carcinoma (la/mUC).
Enfortumab vedotin-pembrolizumab beats chemo as 1L Tx for bladder cancer
03 Nov 2023
Biomarker-driven therapies superior to standard care in breast cancer
Patients with breast cancer may gain greater therapeutic advantages from biomarker-driven than standard-of-care therapies, suggests a study.
Biomarker-driven therapies superior to standard care in breast cancer
02 Nov 2023
Esketamine outperforms quetiapine in head-to-head depression trial
In patients with treatment-resistant depression, esketamine nasal spray appears to have superior efficacy compared with extended-release quetiapine when used in combination with conventional antidepressants.
Esketamine outperforms quetiapine in head-to-head depression trial
30 Oct 2023
Antiviral therapy safe, effective in children with immune-tolerant HBV infection
Treatment with antiviral therapy is beneficial and generally tolerated in children with chronic hepatitis B virus (HBV) infection in the immune-tolerant stage, according to the results of a systematic review and meta-analysis.
Antiviral therapy safe, effective in children with immune-tolerant HBV infection
28 Oct 2023
Canagliflozin holds promise against MAFLD in T2D patients
Patients with type 2 diabetes (T2D) who received canagliflozin benefit from improved liver biochemistry and metabolism, a recent study has shown. In addition, treatment with canagliflozin appears to confer positive effects on liver fibrosis.